The status of materials isolated physically or by other effective means pending a decision on their subsequent approval or rejection.
Glossary
Quarantine
02.27.12
-
Promotions & Moves
Akebia Therapeutics Names CMO
Jain to lead clinical development of the company’s HIF pipeline
-
Financial Reports
Financial Report: Biogen
TECFIDERA revenues up 9% to $4.0 billion
-
Quality Risk Management
Embracing the process as a means to a strong quality cultureCheryl Abernathy and Bryan Sasbon, Quality Assurance Operations Manager, Ropack Pharma Solutions; QA Director & Regulatory Affairs, Ropack Pharma Solutions
-
Industry News
Astellas Transfers U.S. Mfg. Subsidiary to Avara
Plant will continue to manufacture certain Astellas products on a contract basis
-
Biologics, Proteins, Vaccines | Biosimilars | cGMP Manufacture | Drug Development
The Changing Biopharma Risk Landscape
Highlights biopharma industry's growth drivers and new approaches for mitigating risk
